20/20 Biolabs Inc

AIDX

Market cap $9.2M

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) (“20/20 Biolabs” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that its OneTest™ multi-cancer early detection blood (“MCED”) test has been selected as part of a firefighter cancer screening initiative for the state of Vermont in partnership with National Diagnostic Services (“NDS”).

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed  GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) (“20/20 Biolabs” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced that it is developing contingency plans to establish Ebola and Hantavirus testing in its CAP-accredited CLIA laboratory if called upon to support or augment testing by public health laboratories.

State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent Strategic Wins Include Evexia Diagnostics Distribution Agreement, ROKIT Healthcare CKD License, and Commercial Launch of OneTest™ for Longevity GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the first quarter ended March 31, 2026.

GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that management will attend the upcoming Sidoti Micro-Cap Virtual Conference.

Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results Licensing Agreement Expands 20/20 BioLabs' AI-Enabled Multi-Cancer Early Detection Platform GAITHERSBURG, Md., May 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive, worldwide licensing agreement with the University of South Carolina to commercialize a patented algorithm developed by a team headed by James Hébert, Sc.D.

Healwell AI Inc. (AIDX:CA) Q1 2026 Earnings Call Transcript

Joint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Functional and Integrative Medicine Practitioners Marks a Commercial Expansion Milestone for OneTest for Cancer Across Evexia's National Practitioner Network WASHINGTON, Conn. and GAITHERSBURG, Md.

Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-Funded Firefighter Cancer Screening Program Expected to Drive Significant Revenue Growth in Q2 and Full Year 2026 Recent Nasdaq Listing Under Ticker Symbol “AIDX” and New Growth Initiatives Position 20/20 BioLabs for 2026 Expansion GAITHERSBURG, Md., March 31, 2026 (GLOBE NEWSWIRE) --  20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today reported its financial and operational results for the full year ended December 31, 2025.

State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools  GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that 18 groups of Maryland fire departments have been notified that they will collectively be awarded over $520,000 from the Maryland Department of Health (MDH) to procure and administer the Company's patented OneTest™ multi-cancer early detection (MCED) blood test.

Inflammatory Biomarker Tracking Predicted to Enhance  Response to 3-D Bio-Printed Therapies Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment GAITHERSBURG, Md., March 24, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”), 20/20 BioLabs (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare Inc. (“ROKIT”), a global innovator in chronic disease prediction and regenerative health technologies.